EP
AQST icon

Essential Partners’s Aquestive Therapeutics AQST Stock Holding History

Essential Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196 Hold
47
– – ﹤0.01% 2640
2026
Q1 		$195 Hold
47
– – ﹤0.01% 2614
2025
Q4 		$304 Hold
47
– – ﹤0.01% 2337
2025
Q3 		$263 Hold
47
– – ﹤0.01% 2350
2025
Q2 		$156 Buy
+47
New +$135 ﹤0.01% 1997

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Essential Partners's AQST Position: Q2 2026 in Review

Essential Partners held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 47 shares worth $196. The position accounts for ﹤0.01% of the portfolio, ranked #2640.

Essential Partners first reported a position in AQST in Q2 2025 and has held it in 5 quarters since. The position peaked at $304 in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Essential Partners held 47 shares of Aquestive Therapeutics worth $196 as of Q2 2026.
  • Essential Partners left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2640 holding.
  • Essential Partners first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Aquestive Therapeutics position peaked at $304 in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.